Loading
Unilateral Resistance Training / Obesity (BMI > 35) · Interventional Study
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a planned 13-week interventional pilot study that has not yet begun recruitment. The study will investigate whether supervised unilateral resistance training can preserve skeletal muscle mass during incretin agonist therapy in adults with obesity, using an internal control design (contralateral leg). No results are available, and the study design and sample size are suitable only for preliminary feasibility and proof-of-concept, not for practice guidance.
Interventional, Single Group, Open label, Treatment purpose. Obesity (BMI > 35); age from 18 Years; to 64 Years. Intervention: Incretin treatment combined with unilateral resistance trai…. Compared with: Contralateral untrained leg (internal control).. n = 20. 1 site: Sweden.
This is a registry record for a planned 13-week interventional pilot study that has not yet begun recruitment. The study will investigate whether supervised unilateral resistance training can preserve skeletal muscle mass during incretin agonist therapy in adults with obesity, using an internal control design (contralateral leg). No results are available, and the study design and sample size are suitable only for preliminary feasibility and proof-of-concept, not for practice guidance.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study is preparatory work. Results, when available, may inform whether resistance training during incretin therapy is feasible and protective of muscle mass, but a pilot of 20 participants cannot establish clinical benefit or change practice. Clinicians should await larger confirmatory trials before recommending resistance training specifically for this indication.
This is an unstarted interventional registry record with no results posted; it describes a planned small pilot study (n=20) investigating a novel application of resistance training during incretin agonist therapy, with surrogate endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This study is preparatory work. Results, when available, may inform whether resistance training during incretin therapy is feasible and protective of muscle mass, but a pilot of 20 participants cannot establish clinical benefit or change practice. Clinicians should await larger confirmatory trials before recommending resistance training specifically for this indication.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07761923). This is a study registration, not published results. Lead sponsor: Karolinska Institutet. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Obesity (BMI > 35). Interventions: BEHAVIORAL: Unilateral Resistance Training. Primary outcome measures: Change in Anterior Thigh Skeletal Muscle Volume , From baseline to 13 weeks. Brief summary: Treatment with appetite suppressant drugs, including incretin-based receptor agonists, generally leads to clinically meaningful weight loss and reduced cardiometabolic risk. However, weight loss may include not only loss of adipose tissue but also loss of skeletal muscle mass, which ultimately may impair physical function and metabolic health. Resistance training is an effective strategy to maintain or increase skeletal muscle mass during weight loss, but its effects during treatment with appetite suppressant obesity medications have been studied insufficiently. This study will investigate whether unilateral resistance training during incretin-based receptor agonist treatment can preserve or improve skeletal muscle mass. Additionally, the study will determine whether preservation of muscle is accompanied by the preservation of muscle function and/or molecular adaptations in skeletal muscle, adipose tissue and blood. Participants will be adults with obesity who are about to start treatment with an incretin-based receptor agonist as part of routine clinical care. During the 13-week intervention, participants will perform supervised unilateral resistance training two times per week, training one leg while the other leg serves as an internal control. Data and tissue collection will take place before treatment start and after 13 weeks. Assessments include whole-body magnetic resonance imaging, blood sampling, skeletal muscle and adipose tissue biopsies, physical function tests, questionnaires, and monitoring of physical activity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.